Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy-Reference-Cited by-同舟云学术

Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy

Published:2015-12 Issue:6 Volume:106 Page:348-354
ISSN:0888-7543
Container-title:Genomics
language:en
Short-container-title:Genomics

Author:

Pfütze Katrin,Benner Axel,Hoffmeister Michael,Jansen Lina,Yang Rongxi,Bläker Hendrik,Herpel Esther,Ulrich Alexis,Ulrich Cornelia M.,Chang-Claude Jenny,Brenner Hermann,Burwinkel Barbara

Funder

German Research Council

German Federal Ministry of Education and Research

Publisher

Elsevier BV

Subject

Genetics

Reference51 articles.

1. Cancer statistics, 2008;Jemal;Ca Cancer J. Clin.,2008

2. Cancer statistics;Siegel;CA Cancer J. Clin.,2015

3. Molecular heterogeneity of colorectal cancer: Implications for cancer control;Jass;Surg. Oncol.,2007

4. Adjuvant therapy in colon cancer;Graham;Expert. Rev. Anticancer. Ther.,2012

5. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer;Van Rijnsoever;Clin. Cancer Res.,2003

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alteration in DNA methylation patterns: Epigenetic signatures in gastrointestinal cancers;European Journal of Pharmacology;2024-06

2. Methylation-Based Therapies for Colorectal Cancer;Cells;2020-06-24

3. Multiple gene promoter methylation and clinical stage in adjacent normal tissues: Effect on prognosis of colorectal cancer in Taiwan;Scientific Reports;2020-01-10

4. Temporal DNA methylation pattern and targeted therapy in colitis-associated cancer;Carcinogenesis;2019-12-05

5. Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies;International Journal of Molecular Sciences;2019-08-06